Examedi vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 37)
Examedi logo

Examedi

EmergingHealthcare

General

Santiago digital healthcare marketplace connecting LatAm patients with home labs, telemedicine, and specialist booking at $14.9M revenue; YC-backed with M&A offer received April 2025 across Chile, Mexico, Colombia.

AI VisibilityBeta
Overall Score
D37
Category Rank
#487 of 596
AI Consensus
82%
Trend
stable
Per Platform
ChatGPT
36
Perplexity
31
Gemini
34

About

Examedi is a Santiago, Chile-based digital healthcare marketplace — backed by Y Combinator with $14.9 million in revenue in 2024, having received an M&A offer in April 2025 — connecting patients across Latin America with on-demand healthcare services including lab testing at home, telemedicine consultations, home nursing visits, and specialist appointments through a marketplace model that coordinates healthcare workers, labs, and facilities. Founded in 2021 by Andres Kemeny and Juan Pablo Zepeda, Examedi serves patients, employers, health plans, and healthcare facilities throughout Chile, Mexico, Colombia, and broader Latin America as a healthcare access intermediary.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

37
Overall Score
90
#487
Category Rank
#2
82
AI Consensus
83
stable
Trend
stable
36
ChatGPT
92
31
Perplexity
93
34
Gemini
89
36
Claude
96
39
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.